Difference between revisions of "Darbepoetin alfa (Aranesp)"
Jump to navigation
Jump to search
m (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>") |
m |
||
| (19 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.<ref name="insert">[http://pi.amgen.com/united_states/aranesp/ckd/aranesp_pi_hcp_english.pdf Darbepoetin alfa (Aranesp) package insert]</ref><ref>[ | + | Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.<ref name="insert">[http://pi.amgen.com/united_states/aranesp/ckd/aranesp_pi_hcp_english.pdf Darbepoetin alfa (Aranesp) package insert]</ref><ref>[[:File:Darbepoetin.pdf | Darbepoetin alfa (Aranesp) package insert (locally hosted backup)]]</ref><ref>[http://www.aranesp.com/ Aranesp manufacturer's website]</ref><ref>As of 4/14/2017, use of this medication in patients with oncologic diagnoses no longer requires enrollment in the ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program</ref> |
<br>Route: SC, IV | <br>Route: SC, IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | + | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Myelodysplastic syndrome]] | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://pi.amgen.com/united_states/aranesp/ckd/aranesp_pi_hcp_english.pdf Darbepoetin alfa (Aranesp) package insert]<ref name="insert"></ref> | ||
| + | *[https://chemocare.com/druginfo/darbepoetin-alfa.aspx Darbepoetin alfa (Aranesp) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/darbepoetin-alfa.aspx Darbepoetin alfa (Aranesp) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/darbepoetin-alfa-patient-drug-information Darbepoetin alfa (Aranesp) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/darbepoetin-alfa-patient-drug-information Darbepoetin alfa (Aranesp) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/darbepoetin-alfa-patient-drug-information Darbepoetin alfa (Aranesp) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/darbepoetin-alfa-patient-drug-information Darbepoetin alfa (Aranesp) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in PMDA indication== | ||
| + | *2014-12-18: New additional indication and a new dosage for the treatment of anemia due to myelodysplastic syndrome. | ||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Actorise, Aranesp, Bionesp, Cresp, Darbetin, Darbex, Derise, Kabidarba, Nesp, Nespo | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Subcutaneous medications]] | ||
| + | [[Category:Intravenous medications]] | ||
| + | [[Category:Hematopoietic growth factors]] | ||
| + | [[Category:Erythrocyte growth factors]] | ||
| + | |||
| + | [[Category:Myelodysplastic syndrome medications]] | ||
| + | |||
| + | [[Category:FDA approved in 2001]] | ||
Revision as of 10:29, 28 May 2024
General information
Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.[1][2][3][4]
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Darbepoetin alfa (Aranesp) package insert[1]
- Darbepoetin alfa (Aranesp) patient drug information (Chemocare)[5]
- Darbepoetin alfa (Aranesp) patient drug information (UpToDate)[6]
History of changes in PMDA indication
- 2014-12-18: New additional indication and a new dosage for the treatment of anemia due to myelodysplastic syndrome.
Also known as
- Brand names: Actorise, Aranesp, Bionesp, Cresp, Darbetin, Darbex, Derise, Kabidarba, Nesp, Nespo
References
- ↑ 1.0 1.1 1.2 Darbepoetin alfa (Aranesp) package insert
- ↑ Darbepoetin alfa (Aranesp) package insert (locally hosted backup)
- ↑ Aranesp manufacturer's website
- ↑ As of 4/14/2017, use of this medication in patients with oncologic diagnoses no longer requires enrollment in the ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program
- ↑ Darbepoetin alfa (Aranesp) patient drug information (Chemocare)
- ↑ Darbepoetin alfa (Aranesp) patient drug information (UpToDate)